CFMS Stock Price
CFMS RSI Chart
CFMS Valuation
CFMS Price/Sales (Trailing)
CFMS Profitability
CFMS Fundamentals
CFMS Revenue
CFMS Earnings
Price Action
Last 30 days
0.9%
Last 90 days
100%
Trailing 12 Months
-65.2%
CFMS Financial Health
CFMS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CFMS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-05 | Fischetti Gary P | back to issuer | - | - | -10,470 | - |
2023-09-05 | JOHNSTON PHILIP W | back to issuer | - | - | -19,273 | - |
2023-09-05 | Augusti Mark A | acquired | - | - | 17,778 | former president & ceo |
2023-09-05 | BIENKOWSKI CARRIE | back to issuer | - | - | -19,909 | - |
2023-09-05 | Augusti Mark A | back to issuer | - | - | -190,277 | former president & ceo |
2023-09-05 | Langdale Bradley | back to issuer | - | - | -18,379 | - |
2023-09-05 | Pedulla Denise E | back to issuer | - | - | -18,000 | former clo & secretary |
2023-09-05 | Desrochers Christine | back to issuer | - | - | -81,465 | fmr interim cfo & controller |
2023-09-05 | FALLON KENNETH P III | back to issuer | - | - | -20,320 | - |
2023-04-25 | Augusti Mark A | acquired | - | - | 75,150 | president & ceo |
Which funds bought or sold CFMS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -24.88 | 44.00 | 2,010 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 1.52 | 80.00 | 293 | -% |
2023-08-14 | IFP Advisors, Inc | added | 100 | 3,329 | 5,487 | -% |
2023-08-14 | VANGUARD GROUP INC | reduced | -63.65 | -240,671 | 235,357 | -% |
2023-08-14 | MILLENNIUM MANAGEMENT LLC | sold off | -100 | -18,000 | - | -% |
2023-08-14 | Tower Research Capital LLC (TRC) | added | 1.5 | 3,721 | 11,721 | -% |
2023-08-14 | NewEdge Advisors, LLC | unchanged | - | 1,218 | 4,599 | -% |
2023-08-14 | Steward Partners Investment Advisory, LLC | unchanged | - | 3.00 | 9.00 | -% |
2023-08-14 | OPTIONS SOLUTIONS, LLC | new | - | 1,213 | 1,213 | -% |
2023-08-14 | MORGAN STANLEY | added | 182 | 6,620 | 8,948 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of ConforMIS
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jul 10, 2023 | wasatch advisors lp | - | 0 | SC 13G/A | |
| Feb 14, 2023 | armistice capital, llc | 6.00% | 480,000 | SC 13G/A | |
| Feb 13, 2023 | stonepine capital management, llc | 9.9% | 748,194 | SC 13G/A | |
| Feb 09, 2023 | wasatch advisors inc | - | 0 | SC 13G | |
| Apr 07, 2022 | wasatch advisors inc | - | 0 | SC 13G/A | |
| Feb 15, 2022 | armistice capital, llc | 6.1% | 1.2e+07 | SC 13G/A | |
| Feb 14, 2022 | stonepine capital management, llc | 7.9% | 14,768,823 | SC 13G/A | |
| Feb 11, 2022 | wasatch advisors inc | - | 0 | SC 13G | |
| Feb 09, 2022 | ark investment management llc | 6.81% | 12,681,400 | SC 13G | |
| Jun 14, 2021 | stonepine capital management, llc | 5.0% | 9,161,871 | SC 13G |
Recent SEC filings of ConforMIS
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 15, 2023 | 15-12G | 15-12G | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 05, 2023 | S-8 POS | Employee Benefits Plan |
Peers (Alternatives to ConforMIS)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 109.7B | 19.5B | 4.61% | 32.58% | 40.5 | 5.64 | 10.36% | 30.30% |
MDT | 108.4B | 31.6B | -0.16% | -7.89% | 29.89 | 3.44 | 1.57% | -30.40% |
ISRG | 102.6B | 6.7B | 1.85% | 46.31% | 71.98 | 15.39 | 11.75% | -0.66% |
BDX | 71.3B | 19.0B | -3.08% | 10.26% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 43.7B | 5.7B | -5.74% | -17.48% | 31.48 | 7.73 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 10.1B | 937.8M | 5.52% | 36.72% | 345.25 | 10.72 | 16.30% | 250.21% |
SWAV | 7.5B | 616.6M | -7.14% | -29.65% | 30.68 | 12.13 | 69.52% | 343.68% |
GMED | 5.3B | 1.1B | -4.57% | -12.56% | 25.23 | 4.84 | 12.63% | 50.85% |
IRTC | 2.7B | 452.1M | -16.85% | -42.51% | -27.51 | 6.04 | 24.99% | 24.09% |
TNDM | 1.5B | 790.3M | -18.06% | -57.30% | -6.6 | 1.87 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
AVNS | 952.1M | 780.7M | -7.00% | -11.88% | -26.45 | 1.22 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 620.2M | 162.9M | -26.12% | -63.06% | -11.73 | 3.81 | 42.67% | 12.82% |
BLFS | 551.7M | 162.2M | 16.09% | -48.52% | -6.56 | 3.4 | 9.71% | 12.37% |
ConforMIS News
Returns for CFMS
Cumulative Returns on CFMS
-47.4%
7-Year Cumulative Returns
-40.6%
5-Year Cumulative Returns
-49.4%
3-Year Cumulative Returns
Risks for CFMS
What is the probability of a big loss on CFMS?
100%
Probability that ConforMIS stock will be more than 20% underwater in next one year
100%
Probability that ConforMIS stock will be more than 30% underwater in next one year.
95.4%
Probability that ConforMIS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CFMS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if ConforMIS was unfortunately bought at previous high price.
Drawdowns
Financials for ConforMIS
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -3.8% | 57,064,000 | 59,336,000 | 62,050,000 | 60,054,000 | 60,523,000 | 101,576,000 | 99,860,000 | 101,133,000 | 103,001,000 | 66,121,000 | 68,761,000 | 71,953,000 | 73,135,000 | 73,260,000 | 77,429,000 | 79,589,000 | 91,270,000 | 90,777,000 | 89,789,000 | 88,491,000 | 77,932,000 |
| Gross Profit | -16.1% | 18,949,000 | 22,575,000 | 23,213,000 | 22,006,000 | 23,171,000 | 65,249,000 | 65,681,000 | 67,532,000 | 69,194,000 | 32,674,000 | 33,715,000 | 35,572,000 | 35,516,000 | 34,120,000 | 36,737,000 | 37,949,000 | 50,040,000 | 49,529,000 | 48,485,000 | 46,374,000 | 33,969,000 |
| Operating Expenses | -6.4% | 59,472,000 | 63,546,000 | 69,491,000 | 74,874,000 | 75,417,000 | 73,847,000 | 68,689,000 | 64,822,000 | 62,188,000 | 58,859,000 | 58,829,000 | 58,808,000 | 58,533,000 | 60,733,000 | 61,866,000 | 65,654,000 | 77,407,000 | 82,354,000 | 87,177,000 | 88,388,000 | 82,379,000 |
| S&GA Expenses | -10.5% | 21,195,000 | 23,694,000 | 25,308,000 | 25,842,000 | 26,714,000 | 26,456,000 | 24,904,000 | 24,077,000 | 23,398,000 | 21,196,000 | 22,646,000 | 23,703,000 | 24,101,000 | 26,896,000 | 28,514,000 | 30,913,000 | 33,813,000 | 36,725,000 | 38,955,000 | 39,129,000 | 38,817,000 |
| R&D Expenses | -13.5% | 11,519,000 | 13,319,000 | 15,340,000 | 16,166,000 | 16,038,000 | 15,730,000 | 14,791,000 | 14,083,000 | 13,401,000 | 12,489,000 | 11,939,000 | 11,649,000 | 11,945,000 | 12,535,000 | 12,457,000 | 12,860,000 | 13,565,000 | 15,087,000 | 16,869,000 | 17,571,000 | 17,785,000 |
| EBITDA | 100.0% | - | -38,037,000 | -44,445,000 | -55,398,000 | -52,981,000 | 904,000 | 5,447,000 | 13,713,000 | 20,542,000 | -19,666,000 | -17,512,000 | -16,392,000 | -18,994,000 | -22,859,000 | -21,254,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.64 | -0.72 | -0.92 | -0.88 | 0.01 | 0.05 | 0.14 | 0.20 | -0.30 | -0.25 | -0.23 | -0.26 | -0.31 | -0.27 | - | - | - | - | - | - |
| Interest Expenses | 9.8% | 2,420,000 | 2,205,000 | 2,019,000 | 3,124,000 | 3,199,000 | 3,353,000 | 3,496,000 | 2,406,000 | 2,416,000 | 2,393,000 | 2,373,000 | 2,348,000 | 2,310,000 | 3,063,000 | 2,942,000 | 3,430,000 | 3,645,000 | 3,074,000 | 3,356,000 | 3,011,000 | 2,941,000 |
| Earnings Before Taxes | 6.0% | -41,444,000 | -44,088,000 | -50,496,000 | -62,725,000 | -60,494,000 | -6,836,000 | -2,322,000 | 7,010,000 | 13,791,000 | -26,406,000 | -24,251,000 | -23,077,000 | -25,594,000 | -30,171,000 | -28,433,000 | -32,893,000 | -31,623,000 | -38,926,000 | -43,304,000 | -45,260,000 | -50,242,000 |
| EBT Margin | 100.0% | - | -0.74 | -0.81 | -1.04 | -1.00 | -0.07 | -0.02 | 0.07 | 0.13 | -0.40 | -0.35 | -0.32 | -0.35 | -0.41 | -0.37 | - | - | - | - | - | - |
| Net Income | 5.7% | -41,500,000 | -44,013,000 | -50,473,000 | -62,733,000 | -60,504,000 | -6,938,000 | -2,413,000 | 6,941,000 | 13,731,000 | -26,446,000 | -24,293,000 | -23,104,000 | -25,622,000 | -30,250,000 | -28,478,000 | -32,915,000 | -31,651,000 | -38,945,000 | -43,365,000 | -45,353,000 | -50,388,000 |
| Net Income Margin | 100.0% | - | -0.74 | -0.81 | -1.04 | -1.00 | -0.07 | -0.02 | 0.07 | 0.13 | -0.40 | -0.35 | -0.32 | -0.35 | -0.41 | -0.37 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -45,031,000 | -52,071,000 | -34,876,000 | -33,399,000 | -19,611,000 | -10,699,000 | -20,497,000 | -11,686,000 | -24,486,000 | -21,559,000 | -22,439,000 | -11,379,000 | -6,724,000 | -5,764,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -17.3% | 68.00 | 82.00 | 94.00 | 105 | 117 | 129 | 145 | 158 | 169 | 146 | 72.00 | 80.00 | 68.00 | 64.00 | 72.00 | 73.00 | 65.00 | 64.00 | 63.00 | 86.00 | 94.00 |
| Current Assets | -19.2% | 55.00 | 68.00 | 79.00 | 89.00 | 101 | 111 | 127 | 138 | 149 | 129 | 53.00 | 61.00 | 48.00 | 44.00 | 53.00 | 53.00 | 44.00 | 43.00 | 48.00 | 71.00 | 70.00 |
| Cash Equivalents | -30.7% | 26.00 | 38.00 | 49.00 | 60.00 | 73.00 | 83.00 | 101 | 98.00 | 109 | 105 | 29.00 | 33.00 | 19.00 | 22.00 | 27.00 | 29.00 | 30.00 | 19.00 | 17.00 | 22.00 | 29.00 |
| Inventory | -2.4% | 19.00 | 19.00 | 19.00 | 18.00 | 17.00 | 16.00 | 15.00 | 14.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 12.00 | 12.00 | 12.00 | 11.00 | 10.00 | 10.00 | 10.00 | 9.00 |
| Net PPE | -7.5% | 7.00 | 8.00 | 8.00 | 9.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 | 12.00 | 12.00 | 13.00 | 14.00 | 14.00 | 13.00 | 13.00 | 14.00 | 14.00 | 14.00 | 15.00 | 17.00 |
| Goodwill | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00 |
| Liabilities | -4.1% | 36.00 | 37.00 | 40.00 | 43.00 | 44.00 | 43.00 | 45.00 | 43.00 | 43.00 | 59.00 | 60.00 | 61.00 | 59.00 | 54.00 | 56.00 | 53.00 | 38.00 | 34.00 | 27.00 | 43.00 | 45.00 |
| Current Liabilities | -9.0% | 11.00 | 12.00 | 14.00 | 18.00 | 18.00 | 16.00 | 18.00 | 15.00 | 15.00 | 30.00 | 31.00 | 32.00 | 30.00 | 16.00 | 18.00 | 17.00 | 13.00 | 14.00 | 11.00 | 12.00 | 15.00 |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | - | - | - |
| LT Debt, Non Current | 0.2% | 21.00 | 21.00 | 21.00 | 20.00 | 20.00 | 20.00 | 20.00 | 21.00 | 21.00 | 25.00 | 25.00 | 25.00 | 25.00 | 20.00 | 20.00 | 19.00 | 19.00 | 14.00 | 15.00 | 30.00 | 30.00 |
| Shareholder's Equity | -28.2% | 32.00 | 45.00 | 54.00 | 61.00 | 73.00 | 86.00 | 101 | 115 | 126 | 87.00 | 11.00 | 19.00 | 8.00 | 10.00 | 16.00 | 20.00 | 27.00 | 30.00 | 36.00 | 43.00 | 49.00 |
| Retained Earnings | -2.2% | -603 | -590 | -581 | -577 | -562 | -546 | -530 | -514 | -501 | -539 | -528 | -521 | -515 | -513 | -504 | -498 | -490 | -483 | -475 | -465 | -458 |
| Additional Paid-In Capital | 0.1% | 636 | 635 | 635 | 635 | 634 | 633 | 633 | 631 | 630 | 630 | 544 | 543 | 525 | 523 | 521 | 519 | 519 | 514 | 513 | 511 | 510 |
| Shares Outstanding | 5.1% | 8.00 | 7.00 | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -3.8% | -44,528 | -42,898 | -50,153 | -32,811 | -31,070 | -16,984 | -8,399 | -18,417 | -10,064 | -22,349 | -18,310 | -18,614 | -6,997 | -3,078 | -2,838 | 3,580 | -15,775 | -21,414 | -25,176 | -34,929 | -34,417 |
| Share Based Compensation | -20.4% | 1,605 | 2,017 | 2,132 | 3,417 | 3,647 | 3,632 | 3,815 | 3,600 | 3,546 | 3,559 | 3,406 | 3,241 | 2,342 | 2,455 | 2,837 | 3,321 | 4,208 | 4,161 | 3,886 | 4,643 | 5,091 |
| Cashflow From Investing | -0.5% | -2,143 | -2,133 | -1,918 | -2,065 | -2,329 | -2,627 | -2,300 | -2,080 | -1,622 | -2,137 | -3,249 | -3,825 | -4,216 | -3,646 | 4,324 | 12,074 | 14,521 | 15,768 | 15,626 | 8,592 | 4,372 |
| Cashflow From Financing | - | - | - | - | -2,087 | -2,073 | -2,092 | 82,803 | 84,890 | 101,899 | 107,511 | 23,757 | 25,819 | 8,744 | 9,668 | 8,527 | -7,816 | -7,264 | -13,669 | 7,655 | 21,942 | 21,529 |
CFMS Income Statement
2023-06-30Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |||
| Revenue | ||||||
| Total revenue | $ 13,023 | $ 15,295 | $ 25,860 | $ 30,846 | ||
| Cost of revenue | 11,189 | 9,835 | 18,923 | 19,645 | ||
| Gross profit | 1,834 | 5,460 | 6,937 | 11,201 | ||
| Operating expenses | ||||||
| Sales and marketing | 4,063 | 6,562 | 9,114 | 13,227 | ||
| Research and development | 2,158 | 3,958 | 4,616 | 8,437 | ||
| General and administrative | 7,918 | 7,693 | 14,941 | 17,026 | ||
| Total operating expenses | 14,139 | 18,213 | 28,671 | 38,690 | ||
| Loss from operations | (12,305) | (12,753) | (21,734) | (27,489) | ||
| Other income and expenses | ||||||
| Interest income | 6 | 14 | 15 | 31 | ||
| Interest expense | (668) | (453) | (1,305) | (904) | ||
| Foreign currency exchange transaction (loss) income | (13) | (2,432) | 455 | (3,259) | ||
| Total other expenses | (675) | (2,871) | (835) | (4,132) | ||
| Loss before income taxes | (12,980) | (15,624) | (22,569) | (31,621) | ||
| Income tax (benefit) provision | 31 | (100) | 13 | (66) | ||
| Net loss | $ (13,011) | $ (15,524) | $ (22,582) | $ (31,555) | ||
| Net loss per share - basic (in dollars per share) | [1] | $ (1.78) | $ (2.15) | $ (3.10) | $ (4.39) | |
| Net loss per share - diluted (in dollars per share) | [1] | $ (1.78) | $ (2.15) | $ (3.10) | $ (4.39) | |
| Weighted average common shares outstanding - basic (in shares) | [1] | 7,316,286 | 7,211,851 | 7,291,542 | 7,189,634 | |
| Weighted average common shares outstanding - diluted (in shares) | [1] | 7,316,286 | 7,211,851 | 7,291,542 | 7,189,634 | |
| Product | ||||||
| Revenue | ||||||
| Total revenue | $ 12,496 | $ 15,142 | $ 25,187 | $ 30,026 | ||
| Royalty and licensing | ||||||
| Revenue | ||||||
| Total revenue | $ 527 | $ 153 | $ 673 | $ 820 | ||
| ||||||
CFMS Balance Sheet
2023-06-30Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets | ||
| Cash and cash equivalents | $ 26,182 | $ 48,667 |
| Accounts receivable, net | 7,676 | 9,773 |
| Royalty and licensing receivable | 121 | 134 |
| Inventories, net | 19,024 | 18,910 |
| Prepaid expenses and other current assets | 1,616 | 1,785 |
| Total current assets | 54,619 | 79,269 |
| Property and equipment, net | 7,455 | 8,154 |
| Operating lease right-of-use assets | 5,159 | 6,078 |
| Other Assets | ||
| Restricted cash | 462 | 462 |
| Other long-term assets | 86 | 85 |
| Total assets | 67,781 | 94,048 |
| Current liabilities | ||
| Accounts payable | 3,584 | 4,163 |
| Accrued expenses | 5,252 | 7,978 |
| Operating lease liabilities | 1,936 | 1,932 |
| Total current liabilities | 10,772 | 14,073 |
| Other long-term liabilities | 336 | 230 |
| Long-term debt, less debt issuance costs | 20,639 | 20,563 |
| Operating lease liabilities | 4,009 | 5,003 |
| Total liabilities | 35,756 | 39,869 |
| Commitments and contingencies | ||
| Stockholders’ equity | ||
| Preferred stock, $0.00001 par value: Authorized: 5,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding as of June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.00001 par value: Authorized: 20,000,000 shares authorized at June 30, 2023 and December 31, 2022; 7,878,332 and 7,502,462 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 0 | 0 |
| Additional paid-in capital | 635,703 | 634,647 |
| Accumulated deficit | (603,906) | (581,324) |
| Accumulated other comprehensive income | 228 | 856 |
| Total stockholders’ equity | 32,025 | 54,179 |
| Total liabilities and stockholders’ equity | $ 67,781 | $ 94,048 |
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.